No products in the cart.
Dossiers, Diligence & Deliverables: What Global Buyers Expect from Indian Exporters
India has rightfully earned its title as the ‘Pharmacy of the World’ home to over 3,000 pharmaceutical companies and 10,000+ manufacturing units that deliver quality-assured, cost-effective medicines across the globe. Yet, despite this robust ecosystem, many Indian exporters still struggle to translate buyer interest into lasting international partnerships.
Why do some exporters, despite having the right product lineup and competitive pricing, see deals slip away like sand through their fingers?
The answer lies in mastering three critical pillars that define a globally dependable exporter:
🔹 Dossiers: Your Regulatory Passport
🔹 Diligence: Your Operational Credibility
🔹 Deliverables: Your Execution Reliability
Having worked in the pharmaceutical sector for over three decades, across manufacturing, regulatory, and business development functions in Africa, LATAM, Southeast Asia, and the Middle East, we’ve come to recognize that what sets apart trustworthy exporters from forgettable ones isn’t just pricing or product range.
It’s preparation, professionalism, and follow-through.
Let’s unpack these three cornerstones in depth.
In both regulated and semi-regulated markets, CTD-format dossiers are no longer a luxury they are a necessity. Today, even buyers in traditionally relaxed markets are increasingly insistent on documentation due to rising scrutiny from regulators, NGOs, and institutional buyers.
A product without a dossier is like a traveler without a passport it may hold value but cannot cross borders.
What Global Buyers Expect:
- CTD-format dossiers with Module 1 adapted for the destination country
- WHO-GMP certification or equivalent from recognized regulatory bodies
- Bioequivalence data, or at least a defined timeline for its generation
- Zone IV/IVb stability data (crucial for tropical/subtropical markets)
- Up-to-date regulatory documentation such as CoPPs
Professional Tip:
Prioritize your top 10 SKUs and invest in getting them dossier-ready. Engage professional regulatory consultants if needed. Even when full registration isn’t required upfront, buyers prefer knowing a clear regulatory path exists.
It’s not poor quality that discourages most buyers, it’s unresponsiveness and inconsistency.
Many international buyers echo the same frustration:
“We sent an inquiry and didn’t hear back for two weeks.”
“We asked for stability data, and received only a COA.”
Exporting isn’t just selling it’s project management. It’s about process integrity, timely coordination, and trust.
What Global Buyers Expect:
- Structured product presentations, not generic item lists
- Timely, complete responses (MOQ, price, lead time, availability, incoterms)
- Clear communication on gaps if a dossier isn’t ready, say so
- A service-first attitude that supports their objectives
Professional Tip:
Institute a 48-hour internal SLA for all export inquiries. Share organized product sheets, regulatory status, and key data points. If you’re an SME, responsiveness and flexibility are your edge, don’t squander them due to poor coordination.
You’ve cleared pricing, paperwork is in order, and the PO is issued. Now comes the true test: Can you deliver as promised?
This is where even experienced exporters falter missed timelines, delayed updates, incorrect shipping documentation, or last-minute specification changes.
In exports, one failed shipment can erase years of effort and goodwill.
What Global Buyers Expect:
- Realistic timelines with timely updates on delays
- Batch-to-batch consistency and adherence to agreed specifications
- Accurate export documents (invoice, packing list, CoA, COO, FSC, BoL, etc.)
- Support for artwork adaptation, registration, or tender submissions
Professional Tip:
Treat every PO as the beginning of a long-term relationship. Be proactive. Communicate challenges early and offer alternatives. Dependability not discounts builds long-term recall.
Q1: What’s the biggest red flag for global buyers?
Delayed or vague communication. It signals a lack of professionalism and jeopardizes the buyer’s compliance and timelines.
Q2: Can I export without dossiers for all products?
Yes, selectively. Focus on semi-regulated or post-shipment markets, but always provide clarity on dossier availability or expected timelines.
Q3: How important is regulatory support in securing deals today?
Critical. NGOs, government buyers, and institutional partners demand CoPPs, GMP, and stability data to meet audit requirements.
Q4: Is private labeling important?
Extremely. Many buyers prefer sourcing under their brand. Flexibility in offering multilingual packaging, inserts, and branding significantly boosts your value proposition.
Q5: I’m an SME. How do I compete with big players?
By being quicker, more agile, and more dependable. Use your lean structure as a strength, support it with quality documentation and predictable service.
Final Word: In Exports, You Don’t Just Win Orders You Earn Trust
India’s pharma exports are poised to cross the $50 billion mark in the coming decade. But this growth will not be driven by pricing alone. It will be driven by those who prioritize professionalism, documentation, and service excellence.
If you’re an SME, a new entrant, or a seasoned exporter re-entering global trade the formula is simple:
✅ Be Dossier-Ready
✅ Be Diligent in Communication
✅ Deliver with Consistency
Let’s not be remembered merely as the “low-cost country.”
Let’s become the most dependable export partner in the world.
📩 Share Your Thoughts
Did this blog resonate with you? Was there a section that particularly struck a chord?
If there are topics you’d like us to explore further, we welcome your suggestions.
Let’s shape conversations that empower Indian exporters to rise higher.
📧 Email us directly at hello@pharmet.io
💬 Or connect with us via WhatsApp at: +91 9999091881
STAY HEALTHY, STAY BLESSED!
Leave a Reply